Thyroid Eye Disease
Sling Therapeutics Inc. focuses clinical research on active, moderate to severe thyroid eye disease, with attention to the orbital and inflammatory features that drive eye protrusion and visual discomfort.
- Proptosis
- Orbital inflammation
- Active thyroid eye disease
The sponsor’s studies are centered on outcomes relevant to eye bulging and disease activity in patients with TED.
Ophthalmic Disease Activity
Its research landscape includes clinical evaluation of changes in eye prominence and related signs of disease progression in ophthalmology.
- Eye protrusion
- Clinical response assessment
- Contralateral eye stability
These areas reflect a therapeutic interest in measurable eye-specific outcomes for patients with thyroid-associated orbitopathy.
Endocrine-Related Autoimmune Disease
The sponsor’s trial portfolio also aligns with the treatment of autoimmune conditions linked to thyroid dysfunction, particularly those with prominent ocular involvement.
- Autoimmune eye disease
- Thyroid-associated orbitopathy
- Inflammatory eye manifestations
Research activity is concentrated on therapeutic approaches for disease presentations that combine endocrine and ocular pathology.
Targeted Therapeutic Development
Sling Therapeutics Inc. is engaged in clinical development around a targeted approach for TED, with interest in assessing treatment effects on patient-relevant ocular endpoints.
- Linsitinib
- Therapeutic response in TED
- Moderate to severe disease management
Its research activity is concentrated in clinical operations supporting studies in the United States and other active trial settings.
